Clinical Trials Browser

Non-squamous Non-small Cell Lung Cancer × pembrolizumab × 90 days × Clear all

NCT06627647 2026-05-22

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Phase 3 Recruiting

Non-squamous Non-small Cell Lung Cancer